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1 |  INTRODUCTION
Studies have indicated increased risk of skin cancer in pa-
tients with severe psoriasis1 and after treatment with bio-
logic therapy2 but it is unclear whether biologic therapy is 
associated with recurrence or spread of synchronous cancer 
in patients with psoriasis. Therefore, biologic therapy is not 
widely used in patients with known oncologic conditions. 
A recent case study reported use of ustekinumab in a male 
patient with severe psoriasis and history of malignant mel-
anoma (MM).3 The European guidelines do not prohibit use 
of biologic therapy in patients with recent cancer; however, 
biologic therapy should be used with caution and after con-
sulting an oncologist.4 Patients with severe psoriasis and his-
tory of cancer therefore constitute a group of special concern.
2 |  CASE
We describe a 53‐year‐old woman with severe psoriasis and 
psoriatic arthritis treated with sequential biologic therapy de-
spite recent history of MM with cerebral metastasis. Since 
1987, the patient has been treated for extended periods with 
methotrexate (MTX) and cyclosporine, which was eventually 
discontinued due to lack of response and adverse effects. In 
2003, the patient began treatment with infliximab 4‐5 mg/kg 
every eighth week and 5 mg MTX once weekly. The patient 
experienced complete resolution of symptoms of this treat-
ment. In 2009, while the patient was still receiving inflixi-
mab she conceived her second child; however, she decided 
to continue infliximab treatment after being thoroughly in-
formed about the possible risks and side effects. She contin-
ued infliximab until gestational week 32. She had a normal 
pregnancy and gave birth to a healthy boy. After delivery, she 
resumed treatment with infliximab.
In September 2016, the patient was diagnosed with a ce-
rebral MM metastasis for which she received neurosurgery 
but not radiation therapy, targeted cancer immunotherapy, or 
chemotherapy. The metastasis was located in the basal gan-
glia/frontal lobe in close proximity to the right ventricle and 
measured 5.3 × 6.2 cm including the surrounding region of 
hemorrhage. It was not possible to locate the primary tumor. 
Infliximab was discontinued, and she was treated with 10 mg 
prednisolone due to increased intracranial pressure and to 
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Abstract
This report of a 53‐year‐old woman with severe psoriasis treated with biologic ther-
apy despite recent history of malignant melanoma with cerebral metastasis suggests 
that biologic therapy for chronic inflammatory diseases may be an option for selected 
patients with recent cancer.
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prevent flare of psoriatic arthritis. After having discontinued 
infliximab during treatment for cancer, the patient returned 
to our department with worsening of psoriasis and had a 
psoriasis area and severity index (PASI) score of 7.8. We 
speculate that flare of psoriasis was due to a combination 
of discontinuation of infliximab and prescription, and sub-
sequently discontinuation, of prednisolone. She was treated 
with 10  mg MTX once per week, which was increased to 
15 mg and then to 25 mg due to lack of response. The PASI 
score increased to 16 and further to 25, and she experienced 
adverse effects of MTX. Due to the lack of control of her 
symptoms, it was investigated whether the patient could be 
treated with secukinumab despite her history of MM aided 
by the local medicine committee at the hospital. The patient 
was thoroughly informed about potential side effects of bi-
ologic treatment including cancer and relapse of previous 
cancer. In April 2017, treatment with secukinumab 300 mg 
weekly in the first 4 weeks and thereafter every month was 
initiated. Before initiating treatment with secukinumab, the 
patient had a PASI score of 25 and a dermatology life quality 
index (DLQI) score of 20. After 3 months of treatment, her 
lesions had fully resolved (PASI = 0) and quality of life had 
improved significantly (DLQI  =  0). The patient continued 
with 300 mg secukinumab every month with good response. 
At 6 months follow‐up, the patient reported only minor flare‐
ups and quality of life was not affected (DLQI = 0). After 
10 months of treatment with secukinumab, the patient expe-
rienced severe worsening of psoriasis with a PASI score of 
18.2, and in March 2018, she discontinued secukinumab and 
initiated treatment with ustekinumab 90 mg every 3 months. 
Ustekinumab was well tolerated and with sustained effec-
tiveness, despite a short‐term guttate flare‐up in December 
2018 with PASI 5 and DLQI 1, until April 2019. No relapse 
of MM has been suspected. She is currently treated with 
ustekinumab.
3 |  COMMENT
In this case of a 53‐year‐old woman with recent history of 
cerebral MM metastasis sequential biologic therapy with 
secukinumab and ustekinumab for almost 2 years was well 
tolerated and apparently not associated with relapse of can-
cer or any other adverse events. Still, every case of severe 
psoriasis and oncologic co‐conditions should be evaluated 
individually before initiating biologic therapy.1 Because se-
vere psoriasis has a great impact on patients’ quality of life, 
biologic therapy may be a treatment option for selected pa-
tients with recent cancer.
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